Consequently, we sought to investigate the potential predictive value of sarcopenia on the efficacy of EGFR-TKIs in NSCLC patients harboring EGFR mutations or of ICIs in patients with wild-type EGFR. The gene discussed is EGFR; the disease is sarcopenia.